Association testing of the 3 TNFAIP3 SNPs among patients with pSS and control patients
| SNP . | Number of minor alleles (%) . | All pSS vs controls . | Lymphoma+ pSS vs controls . | Lymphoma− pSS vs controls . | Lymphoma+ pSS vs lymphoma− pSS . | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Controls (N = 451) . | All pSS patients (N = 574) . | pSS patients without lymphoma (N = 549) . | pSS patients with lymphoma (N = 25) . | OR . | P . | OR . | P . | OR . | P . | OR . | P . | |
| rs13192841 | 243 (28) | 313 (28) | 298 (27) | 15 (30) | 0.94 | .52 | 1.0 | .94 | 0.93 | .50 | 1.12 | .72 |
| rs2230926 | 55 (6) | 73 (6) | 66 (6) | 7 (15) | 1.26 | .24 | 3.36 | .01 | 1.18 | .41 | 3.26 | .011 |
| rs6922466 | 220 (25) | 283 (25) | 272 (25) | 11 (22) | 0.99 | .91 | 0.81 | .56 | 1.0 | .98 | 0.84 | .6 |
| SNP . | Number of minor alleles (%) . | All pSS vs controls . | Lymphoma+ pSS vs controls . | Lymphoma− pSS vs controls . | Lymphoma+ pSS vs lymphoma− pSS . | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Controls (N = 451) . | All pSS patients (N = 574) . | pSS patients without lymphoma (N = 549) . | pSS patients with lymphoma (N = 25) . | OR . | P . | OR . | P . | OR . | P . | OR . | P . | |
| rs13192841 | 243 (28) | 313 (28) | 298 (27) | 15 (30) | 0.94 | .52 | 1.0 | .94 | 0.93 | .50 | 1.12 | .72 |
| rs2230926 | 55 (6) | 73 (6) | 66 (6) | 7 (15) | 1.26 | .24 | 3.36 | .01 | 1.18 | .41 | 3.26 | .011 |
| rs6922466 | 220 (25) | 283 (25) | 272 (25) | 11 (22) | 0.99 | .91 | 0.81 | .56 | 1.0 | .98 | 0.84 | .6 |
Association testing among control patients, all patients with pSS, and patients with patients without lymphoma or with lymphoma using logistic regression adjusting for top 2 PCs of ancestry informative markers. Significant figures are in bold. OR, odds ratio.